Bristol/Medarex’s Ipilimumab Toxic, But Could Extend Life
This article was originally published in The Pink Sheet Daily
Executive Summary
Melanoma drug’s side effects indicate immune-boosting cancer drug’s effectiveness, investigator tells “The Pink Sheet” DAILY.
You may also be interested in...
Medarex/Bristol Myers Squibbs’ Ipilimumab Shows Off Long-Term Survival Data At ASCO
Data from a separate Phase II combination study also add to hopes for a positive outcome in the ongoing Phase III.
Medarex/Bristol Myers Squibbs’ Ipilimumab Shows Off Long-Term Survival Data At ASCO
Data from a separate Phase II combination study also add to hopes for a positive outcome in the ongoing Phase III.
Medarex/Bristol's Ipilimumab Shows Off Long-Term Survival Data At ASCO
Two-year melanoma survival data from three Phase II studies of Medarex/Bristol-Myers Squibbs' immunotherapeutic ipilimumab presented at the American Society of Clinical Oncology meeting May 31 bode well for an ongoing pivotal Phase III study and an eventual first approval for the oncologic